Karuna Therapeutics, Inc. (KRTX) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Boston, MA, United States. Der aktuelle CEO ist William Meury.
KRTX hat IPO-Datum 2019-06-28, 339 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $12.6B.
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines for psychiatric and neurological disorders. The company's lead product candidate, KarXT, is an oral muscarinic receptor modulator currently in Phase III clinical trials for treating acute psychosis in schizophrenia patients, as well as negative and cognitive symptoms associated with schizophrenia, psychosis, and dementia-related psychosis. Karuna has established strategic partnerships with major pharmaceutical and research organizations, including Eli Lilly and Company, Zai Lab, PureTech Health, Charles River Laboratories, and PsychoGenics, Inc. Based in Boston, Massachusetts, the company was incorporated in 2009 and rebranded as Karuna Therapeutics in 2019 to reflect its expanded therapeutic focus.
